When was Orbis Medicines founded?

Orbis Medicines was founded in 2022 and raised its 1st funding round 2 years after it was founded.

Where is Orbis Medicines located?

Orbis Medicines is headquartered in Copenhagen, Denmark.

Who is the current CEO of Orbis Medicines?

Morten Graugaard of Orbis Medicines.

Is Orbis Medicines a funded company?

Orbis Medicines is a funded company, having raised a total of $126M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 29, 2024.

When was the latest funding round of Orbis Medicines?

Orbis Medicines' latest funding was a $***** Series A round on Sep 17, 2026, with participation from 1 investor.

Where does Orbis Medicines rank among its competitors?

Orbis Medicines ranks 16th amongst 64 active competitors, of which 15 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Cingulate, which secured $25M in Jul, 2025.

Who are the top competitors of Orbis Medicines?

Orbis Medicines' top competitors include Cure Pharmaceutical, Cingulate and Vivtex. Among them, Orbis Medicines secured the most recent funding round in September, 2026.

Orbis Medicines - 2026 Company Profile, Team, Funding, Competitors & Financials

Orbis Medicines is a series A company based in Copenhagen (Denmark), founded in 2022 by Sevan Habeshian. It operates as a Provider of drug discovery platform to develop multiple therapeutics. Orbis Medicines has raised $126M in funding from investors like New Enterprise Associates, Forbion and Novo Holdings. The company has 64 active competitors, including 15 funded and 12 that have exited. Its top competitors include companies like Cure Pharmaceutical, Cingulate and Vivtex.

Company Details

Provider of drug discovery platform to develop multiple therapeutics. The company utilizes novel macrocyclic chemistry and computational platforms for high-throughput drug discovery and develop drug candidates for challenging targets.

Website: www.orbismedicines.com/
Email ID: *****@orbismedicines.com

Key Metrics

Founded Year

2022

Location

Copenhagen, Denmark

Stage

Series A

Total Funding

$126M in 3 rounds

Latest Funding Round

Series A, Sep 17, 2026, $*****

Investors

New Enterprise Associates & 5 more

Ranked

16^th among 64 active competitors

Similar Companies

Cure Pharmaceutical & 63 more

View Orbis Medicines' full profile

Orbis Medicines is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Orbis Medicines ApS CIN: 42715646 , Denmark, Active	Sep 27, 2021	-	-

Orbis Medicines has raised a total funding of $126M over 3 rounds. Its first funding round was on Feb 29, 2024. Its latest funding round was a Series A round on Sep 17, 2026 for $*****. 1 investor participated in its latest round. Orbis Medicines has 6 institutional investors.

Here is the list of recent funding rounds of Orbis Medicines:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2026	9043563	Series A	7574454	9981856	5125807	6660183
Jan 06, 2025	5448711	Series A	4853068	8868818	7069893	Lilly & 4 more
Feb 29, 2024	7959313	Seed	1649916	5028128	Novo Holdings & 1 more	4564336

Access funding benchmarks and valuations. Sign up today!

View details of Orbis Medicines's funding rounds and investors

The founders of Orbis Medicines is Sevan Habeshian. Morten Graugaard is the CEO of Orbis Medicines.

Here are the details of Orbis Medicines' key team members:

Sevan Habeshian: Co-Founder of Orbis Medicines.
Contact Info: 1 email address
Morten Graugaard: CEO of Orbis Medicines.

Orbis Medicines' Board of Directors

Orbis Medicines's board has 1 active member. Marco Boorsma is part of team.

Here is the list of Orbis Medicines' board of directors:

Name	Type	Representing	Status	Duration
jzvunrn	Team	-	Current	2y 4m

View details of Orbis Medicines's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orbis Medicines include Cure Pharmaceutical, Cingulate and Vivtex. Here is the list of Top 10 competitors of Orbis Medicines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cure Pharmaceutical 2010, Oxnard (United States), Public	Developer of oral thin film based drug delivery systems	$9.65M	Onbelay Capital, Hangar202 & 1 others	62/100
2nd	Cingulate 2012, Kansas City (United States), Public	Developer of therapeutics for the treatment of ADHD	$33M	The Werth Family Foundation, Lincoln Park Capital ... & 2 others	58/100
3rd	Vivtex 2018, Cambridge (United States), Seed	Developer of oral drug delivery system	$1.8M	-	53/100
4th	Oramed 2006, Jerusalem (Israel), Public	Developer of oral reformulations to treat various health conditions	-	EIC Fund, Europa	51/100
5th	PLx Pharma 2002, Sparta (United States), Public	Developer of drug delivery platform to treat gastrointestinal diseases	$25.3M	Aurus, HHS	49/100
6th	Ingenus 2010, Orlando (United States), Unfunded	Developer of oral drug delivery and drugs for treating cancer	-	-	49/100
7th	G2GBIO 2017, Yuseong District (South Korea), Public	Developer of sustained release injectables	-	Korea Investment Holdings, BNK Venture Capital ... & 1 others	47/100
8th	ThinSol 2017, Hyderabad (India), Series A	Provider of oral thin strips for bioavailability and discreet administration	$4.59M	Reddy Growth & 8 others	46/100
9th	Lipocine 1997, Salt Lake City (United States), Public	Develops oral versions of hormones using Hydroance drug delivery technology	$38M	Foresite Capital	45/100
10th	AcuCort 2006, Helsingborg (Sweden), Unfunded	Developer of dissolving film for treating allergic reactions	-	-	43/100
16th	Orbis Medicines 2022, Copenhagen (Denmark), Series A	Provider of drug discovery platform to develop multiple therapeutics	$126M	Lilly, Cormorant Asset Management & 4 others	54/100